TrialAnnals of surgical oncology2019

Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.

Alice C Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.